Erenumab

Summary

Erenumab (CHEMBL3833329) is an approved antibody (ATC N02CD01); indicated across 6 conditions including migraine disorder and fibromyalgia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: N02CD01
• Indications: 6 conditions
• Clinical trials: 54

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833329
Name	Erenumab
Type	Antibody
Max phase	4
ATC	N02CD01

Also known as: AMG 334, AMG-334, Aimovig, Erenumab, Erenumab aooe, Erenumab-aooe, ERENUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	CGRP receptor	Antagonist	9.1

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
migraine disorder	4	MONDO:0005277	MONDO:0005277
fibromyalgia	3	MONDO:0005546	EFO:0005687
trigeminal neuralgia	2	MONDO:0008599	EFO:1001219
temporomandibular joint disorder	2	MONDO:0005473	EFO:0005279
peripheral nervous system disorder	2	MONDO:0003620	EFO:0004149

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 54.

Phase distribution

Phase	Trials
PHASE4	15
PHASE2	12
Not specified	12
PHASE1	8
PHASE3	7

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03773562	PHASE4	COMPLETED	Imaging the Migraine Brain Pre- and Post-Erenumab
NCT03828539	PHASE4	COMPLETED	Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
NCT03912337	PHASE4	TERMINATED	Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
NCT03971071	PHASE4	COMPLETED	A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
NCT03977649	PHASE4	COMPLETED	A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
NCT04084314	PHASE4	COMPLETED	Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
NCT04252742	PHASE4	COMPLETED	Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
NCT04265755	PHASE4	COMPLETED	Biomarker and Genetic Predictors of Erenumab Treatment Response
NCT04294147	PHASE4	COMPLETED	A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
NCT04465357	PHASE4	COMPLETED	Efficacy of Erenumab on Functional Impact of Migraine
NCT04592952	PHASE4	UNKNOWN	Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab
NCT04603976	PHASE4	UNKNOWN	Registry for Migraine - Clinical Core
NCT04674020	PHASE4	UNKNOWN	Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment
NCT04825678	PHASE4	COMPLETED	A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
NCT05284019	PHASE4	TERMINATED	Real World Effectiveness of Eptinezumab in Participants With Migraine
NCT02456740	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
NCT02483585	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
NCT03333109	PHASE3	COMPLETED	Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
NCT03812224	PHASE3	COMPLETED	A Controlled Trial of Erenumab in Migraine Prevention
NCT03867201	PHASE3	COMPLETED	Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
NCT04114630	PHASE3	WITHDRAWN	Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
NCT06411067	PHASE3	WITHDRAWN	Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain
NCT05049057	PHASE2	RECRUITING	Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
NCT05684692	PHASE2	RECRUITING	Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
NCT01952574	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
NCT02066415	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
NCT02174861	PHASE2	COMPLETED	A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
NCT02575833	PHASE2	COMPLETED	Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
NCT02630459	PHASE2	COMPLETED	A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
NCT04054024	PHASE2	UNKNOWN	Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia
NCT04098250	PHASE2	COMPLETED	Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH
NCT04303845	PHASE2	TERMINATED	Erenumab For Treatment of Hemicrania Continua
NCT04970355	PHASE2	COMPLETED	Efficacy of Erenumab in Chronic Cluster Headache
NCT05142228	PHASE2	TERMINATED	Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
NCT01688739	PHASE1	COMPLETED	Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients
NCT01723514	PHASE1	COMPLETED	Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients
NCT01890109	PHASE1	COMPLETED	Study of Erenumab (AMG 334) in Women With Hot Flashes
NCT02542605	PHASE1	COMPLETED	To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
NCT02741310	PHASE1	COMPLETED	Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan
NCT02792517	PHASE1	COMPLETED	Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).